$20.01
8.22% today
Nasdaq, Feb 28, 08:48 pm CET
ISIN
US86627R1023
Symbol
SMMT
Sector
Industry

Summit Therapeutics PLC Sponsored ADR Stock News

Neutral
PRNewsWire
4 days ago
HONG KONG , Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug con...
Neutral
Seeking Alpha
4 days ago
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Neutral
Seeking Alpha
4 days ago
Pfizer: What The Summit Therapeutics Deal Brings
Neutral
Business Wire
4 days ago
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today reports its financial results and provides an update on operational progress for the fourth quarter and year-ended December 31, 2024. Operational & Corporate Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific ...
Neutral
Business Wire
4 days ago
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings. “Rapidly developing novel mechanisms that go beyond wh...
Neutral
Business Wire
10 days ago
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2024 financial results and provide an operational update for the Company on Monday, February 24, 2025, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which will...
Positive
The Motley Fool
11 days ago
If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.
Neutral
Business Wire
14 days ago
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 116,725 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Compan...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today